Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023

    Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

    May 23, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      India as a Quad-led biomanufacturing hub

      May 25, 2023

      Manappuram Finance, Rossari Biotech shares trade ex-dividend today

      May 24, 2023

      Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

      May 23, 2023

      Israeli biotech phenom puts death knell on cancer

      May 22, 2023

      Six Norwegian companies leading the country’s biotech scene

      May 19, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Pharmaceutical»ED attaches Rs 185 crore worth of assets of Chandigarh pharma company for bank fraud
    Pharmaceutical

    ED attaches Rs 185 crore worth of assets of Chandigarh pharma company for bank fraud

    yourbiotechBy yourbiotechOctober 19, 2022Updated:November 11, 2022No Comments1 Min Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Assets worth more than Rs 185 crore of a Chandigarh-based pharmaceutical company have been attached under the anti-money laundering law in connection with a case of alleged bank loan fraud, the Enforcement Directorate said Tuesday.

    Buildings, plant and machinery of the company, Surya Pharmaceuticals Ltd., and some linked entities have been attached after a provisional order was issued under the Prevention of Money Laundering Act (PMLA).

    The money laundering case stems from two CBI FIRs — filed on the complaint of State Bank of India (SBI), Chandigarh and Punjab and Sind Bank, Karnal — against the company, its managing director Rajiv Goyal and others for “defrauding” the banks to the tune of Rs 828 crore, the federal agency said in a statement.

    The ED said Letters of Credit were availed in the name of the company in lieu of “bogus invoices” and alleged “discounting of these LoCs by associated entities.” “Through a web of fraudulent transactions, the accused siphoned off the proceeds of the credit facilities taken from the banks and used for purchase of various assets in the name of the company, individuals and associated entities,” the ED said.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleinvIOs to present data from clinical stage Cbl-b program at SITC 2022
    Next Article HEALTH AND SCIENCE
    People of color face higher risk of flu hospitalization as U.S. faces potentially severe season, CDC says
    yourbiotech
    • Website

    Related Posts

    Pharma company owner duped of ₹1.1 crore

    November 11, 2022

    Novavax cuts full-year revenue forecast again amid weak demand

    November 10, 2022

    Aurobindo units recall products in US market for manufacturing issues

    November 9, 2022

    AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

    November 8, 2022

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.